Clinical Trial Update: Study of REM-422 in Patients With AML or Higher Risk MDS [Phase 1]

View source ↗

Summary

Remix Therapeutics is conducting a Phase 1 study of REM-422 in patients with myelodysplastic syndromes and acute myeloid leukemia, including refractory AML; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• REM-422

Snippet

Sponsor: Remix Therapeutics | Conditions: Myelodysplastic Syndromes, Higher Risk Myelodysplastic Syndromes | Phase 1 | Status: RECRUITING